Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.35 |
| ▸ | CA2 | P00918 | 7/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11552559 | 0.83 | SMN1; SMN2 (0.37) | CA1CA2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL5710314 | 0.82 | SMN1; SMN2 (0.36) | KDM4EMAPT | |
| SCHEMBL28207903 | 0.81 | CA1 (0.36) | CA1CA2HDAC1HIF1AGRIN1 | |
| SCHEMBL278947 | 0.80 | PPID (0.42) | KDM4EMAPT | |
| SCHEMBL30505642 | 0.80 | PPID (0.42) | KDM4EMAPT | |
| SCHEMBL11550553 | 0.79 | TSHR (0.37) | KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL27767646 | 0.79 | PPID (0.41) | KDM4EMAPT | |
| SCHEMBL28212935 | 0.79 | VSIR (0.37) | CA1MAPT | |
| Hydrochloric Acid SCHEMBL5710126 | 0.79 | PPID (0.41) | KDM4EMAPT | |
| SCHEMBL10603639 | 0.78 | KDM4E (0.42) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0514917-B1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1996-12-27 | — | — | EP | claimed |
| EP-0514917-A1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGIS GYOGYSZERGYAR (HU) | 1992-11-25 | — | — | EP | claimed |
| JP-5271200-A | — | — | None | — | — | JP | disclosed |
| EP-2630148-B1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE LLC (US) | 2020-11-25 | — | — | EP | disclosed |
| CN-107903217-A | A kind of preparation method of anagrelide impurity B | 湖北省宏源药业科技股份有限公司 | 2018-04-13 | — | — | CN | disclosed |
| CN-103180323-B | For the method preparing anagrelide and the like | 夏尔有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| US-8530651-B2 | Process for the preparation of anagrelide and analogues | SHIRE LLC (US) | 2013-09-10 | — | — | US | disclosed |
| EP-2630148-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | Shire LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| CN-103180323-A | Process for the preparation of anagrelide and analogues thereof | SHIRE LLC | 2013-06-26 | — | — | CN | disclosed |
| WO-2012052781-A1 | PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF | SHIRE, LLC (US) | 2012-04-26 | — | — | WO | disclosed |
| CN-102256981-A | Process for the preparation of anagrelide and analogues | SHIRE LLC | 2011-11-23 | — | — | CN | disclosed |
| US-6653500-B2 | Making ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde, reducing the glycine compound using tin dichloride or a catalyst and cyclization of the corresponding iminoquinazoline compound | SHIRE US INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SHIRE US INC. | 2003-03-27 | — | — | US | disclosed |
| US-6388073-B1 | NITRATION A 3,4-DICHLOROBENZALDEHYDE; REDUCING; CHLORINATION; ALKYLATION; BROMOCYANATION; CHLIZATION | SHIRE US INC. | 2002-05-14 | — | — | US | disclosed |
| WO-2002008228-A2 | METHOD FOR THE MANUFACTURE OF ANAGRELIDE | SHIRE US INC (US) | 2002-01-31 | — | — | WO | disclosed |
| EP-0514917-B1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 1996-12-27 | — | — | EP | disclosed |
| US-5391737-A | Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one | EGIS GYOGYSZERGYAR (HU) | 1995-02-21 | — | — | US | disclosed |
| JP-H05271200-A | PRODUCTION OF 6,7-DICHLORO-1,5-DIHYDRO-IMIDAZO(2,1-B)QUINAZOLIN-2(3H)-ONE | EGYT GYOGYSZERVEGYESZETI GYAR | 1993-10-19 | — | — | JP | disclosed |
| EP-0514917-A1 | Process for and 2-(cyanoimino)-quinazoline derivatives useful as intermediates in the preparation of 6,7-di-(chloro)-1,5-di(hydro)-imidazo-[2,1-b]quinazolin-2[3H]-one and process for preparing the 2-(cyanoimino)-quinazoline derivatives | EGIS GYOGYSZERGYAR (HU) | 1992-11-25 | — | — | EP | disclosed |
| US-4146718-A | BLOOD PLATELET ANTIAGGREGATIVE AGENT | BRISTOL-MYERS COMPANY (US) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060630-A1 | Method for the manufacture of Anagrelide | SUCLG2, PDCD2L, ICOSLG | CA1 4119/4885CA2 3760/4885FFAR4 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.